

## **Lupin Receives International Sustainability Rating Standard (ISRS) Certification First Pharmaceutical Company globally to adopt ISRS, 8<sup>th</sup> Edition standard**

**Mumbai, October 18, 2013:** Lupin Limited (Lupin) announced today that the Company has received certification for International Sustainability Rating Standard, 8th edition (ISRS) from Det Norske Veritas (DNV), a global provider of services for managing risk, helping customers to safely and responsibly improve their business performance. The certification was received after audits were conducted at three of the company's manufacturing facilities in India located at Ankleshwar, Mandideep and Tarapur. Lupin is the first pharmaceutical company globally to have received this ISRS 8<sup>th</sup> edition certification

ISRS is a world leading system to assess, improve and demonstrate the health of an organization's business processes. Using ISRS ensures operations are safe and sustainable and helps improve and demonstrate safety, environmental, and sustained business operations / performance.

Commenting on the certification, Mr. Rajendra B. Chunodkar, Executive Vice President, Lupin said, "This certification bears testimony to Lupin's commitment towards adopting best practices in Environment, Health and Safety for Lupin's global manufacturing operations in our mission to remain best-in-class in the Industry. At Lupin, ensuring quality and safety in our business operations remains the cornerstone of all that we do and with this ISRS certification, we are setting a new benchmark for others to follow."

### **About Lupin Limited**

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit <http://www.lupinworld.com> for more information.

### **For more information or any queries, please contact -**

Shamsher Gorawara

Head – Corporate Communications

Lupin Limited

Ph: +91 98 20 338 555

Email: [shamshergorawara@lupinworld.com](mailto:shamshergorawara@lupinworld.com) or

Alpesh Dalal

Head – M & A and Investor Relations

Lupin Limited

Ph: +91 98 20 023 511

Email: [alpeshdalal@lupinpharma.com](mailto:alpeshdalal@lupinpharma.com)